What type of drug is doxorubicin, and what is its major adverse effect?

What type of drug is doxorubicin, and what is its major adverse effect?

• A. An alkylating agent with renal toxicity
• B. An anthracycline with cardiotoxicity
• C. A taxane with gastric distress
• D. A corticosteroid with metabolic syndrome

Answer: (B)

Doxorubicin is classified as an anthracycline, which is a type of chemotherapy drug derived from the bacterium Streptomyces peucetius. Anthracyclines are widely used in cancer treatment due to their efficacy against a variety of tumors, including breast cancer, leukemia, and lymphomas. Their mechanism of action involves intercalating DNA, disrupting the replication and transcription processes, and generating free radicals that can lead to cell death. A significant concern associated with doxorubicin is its potential for cardiotoxicity. This can manifest as acute or chronic damage to the heart muscle, leading to conditions such as cardiomyopathy and congestive heart failure. The risk of cardiotoxicity is dose-dependent, meaning that higher cumulative doses increase the likelihood of adverse cardiac effects. Clinicians regularly monitor cardiac function in patients receiving this medication to mitigate risks and manage any cardiovascular complications that may arise. The other categories mentioned in the choices represent different classes of drugs that are not applicable to doxorubicin. Alkylating agents, taxanes, and corticosteroids have distinct mechanisms of action and side effect profiles. Therefore, the classification of doxorubicin as an anthracycline with potential cardiotoxic side effects is critical

Doxorubicin is classified as an anthracycline, which is a type of chemotherapy drug derived from the bacterium Streptomyces peucetius. Anthracyclines are widely used in cancer treatment due to their efficacy against a variety of tumors, including breast cancer, leukemia, and lymphomas. Their mechanism of action involves intercalating DNA, disrupting the replication and transcription processes, and generating free radicals that can lead to cell death.

A significant concern associated with doxorubicin is its potential for cardiotoxicity. This can manifest as acute or chronic damage to the heart muscle, leading to conditions such as cardiomyopathy and congestive heart failure. The risk of cardiotoxicity is dose-dependent, meaning that higher cumulative doses increase the likelihood of adverse cardiac effects. Clinicians regularly monitor cardiac function in patients receiving this medication to mitigate risks and manage any cardiovascular complications that may arise.

The other categories mentioned in the choices represent different classes of drugs that are not applicable to doxorubicin. Alkylating agents, taxanes, and corticosteroids have distinct mechanisms of action and side effect profiles. Therefore, the classification of doxorubicin as an anthracycline with potential cardiotoxic side effects is critical